tradingkey.logo

OmniAb Inc

OABIW
0.120USD
0.0000.00%
Close 02/06, 16:00ETQuotes delayed by 15 min
0.00Market Cap
--P/E TTM

OmniAb Inc

0.120
0.0000.00%

More Details of OmniAb Inc Company

OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.

OmniAb Inc Info

Ticker SymbolOABIW
Company nameOmniAb Inc
IPO dateOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address5980 Horton Street
CityEMERYVILLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94608
Phone15102507800
Websitehttps://www.omniab.com/
Ticker SymbolOABIW
IPO dateOct 09, 2020
CEOMr. Matthew William (Matt) Foehr

Company Executives of OmniAb Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
--
--
Dr. Jennifer Cochran, Ph.D.
Dr. Jennifer Cochran, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
--
--
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles Stuart Berkman, J.D.
Mr. Charles Stuart Berkman, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
--
--
Mr. Steven C. Crouse
Mr. Steven C. Crouse
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
--
--
Dr. Jennifer Cochran, Ph.D.
Dr. Jennifer Cochran, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
--
--
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Charles Stuart Berkman, J.D.
Mr. Charles Stuart Berkman, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Thu, Oct 2
Updated: Thu, Oct 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%

Institutional Shareholding

Updated: Wed, Jan 21
Updated: Wed, Jan 21
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
12
2.82M
0.00%
--
2025Q4
20
14.18M
0.00%
-3.45M
2025Q3
22
14.23M
0.00%
-3.92M
2025Q2
27
14.22M
0.00%
-4.38M
2025Q1
30
14.22M
0.00%
-4.87M
2024Q4
31
14.27M
0.00%
-4.01M
2024Q3
40
15.02M
0.00%
-4.74M
2024Q2
44
16.42M
0.00%
-4.17M
2024Q1
44
16.68M
0.00%
-3.92M
2023Q4
44
16.86M
0.00%
+8.02M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Walleye Capital LLC
--
0%
-1.63M
-100.00%
Dec 31, 2024
Walleye Trading, LLC
--
0%
-22.51K
-100.00%
Dec 31, 2024
Avista Capital Holdings, LP
11.35M
0%
--
--
Sep 30, 2024
LMR Partners LLP
897.39K
0%
--
--
Sep 30, 2025
Aristeia Capital, L.L.C.
679.92K
0%
-12.80K
-1.85%
Sep 30, 2025
Hudson Bay Capital Management LP
465.23K
0%
--
--
Sep 30, 2025
Sculptor Capital Management, Inc
293.80K
0%
-45.60K
-13.43%
Sep 30, 2025
Calamos Advisors LLC
200.00K
0%
--
--
Sep 30, 2025
MMCAP Asset Management
158.33K
0%
--
--
Sep 30, 2025
Wolverine Asset Management, LLC
11.95K
0%
+11.73K
+5235.27%
Sep 30, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI